Mobile

A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients with Adva...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-002606-18

A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients with Advanced Solid Tumours, Lymphomas and Endometrial Carcinoma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the safety and tolerability of AZD8055 in patients with advanced solid tumours or lymphomas (including 20 patients with endometrial carcinoma in Part B).

Critère d'inclusion

  • Advanced solid tumours, lymphomas and endometrial carcinoma

Liens